Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions

doi:10.1016/0896-6273(93)90070-8

Neuron

Volume 11, Issue 4, October 1993, Pages 575-580

https://doi.org/10.1016/0896-6273(93)90070-8 Get rights and content

Abstract

An increased prevalence of apolipoprotein E (ApoE) ε4 allele exists in late onset familial Alzheimer's disease. We found, in sporadic Alzheimer's disease, that 62% of patients possessed an ApoE-s4 allele, compared with 20% of controls. ApoE-ε4/4 patients had more senile plaques (SPs) than ε3/3 patients. ApoE immunoreactivity of SPs was equivalent in both groups. Two receptors bind ApoE complexes, the low density lipoprotein (LDL) receptor and the LDL receptor-related protein (LRP). In normal brain, anti-LRP antibodies strongly stained neurons and lightly stained astrocytes; anti-LDL receptor antibodies stained only the neuropil and astrocytes. In Alzheimer's disease, SPs and reactive astrocytes were also strongly LRP immunoreactive. Colocalization of ApoE and LRP to SPs implies that these molecules may be involved in metabolism of components of SPs.

References (45)

C.R. Abraham et al.
Immunochemical identification of the serine protease inhibitor α₁-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
Cell
(1988)
J. Bauer et al.
Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
FEBS Lett.
(1991)
U. Beisiegel et al.
Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptormediated endocytosis and the genetics of familial hypercholesterolemia
J. Biol. Chem.
(1981)
J. Hardy et al.
Amyloid deposition as the central event in the aetiology of Alzheimer's disease
Trends Pharmacol. Sci.
(1991)
J. Herz et al.
Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver
J. Biol. Chem.
(1990)
J.E. Hixson et al.
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal
J. Lipid Res.
(1990)
Y. Namba et al.
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
Brain Res.
(1991)
R.E. Pitas et al.
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Biochem. Biophys. Acta
(1987)
J. Poirier et al.
Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning
Mol. Brain Res.
(1991)
D.J. Selkoe
The molecular pathology of Alzheimer's disease
Neuron
(1991)

M.A. Smith et al.

α₁-trypsin immunoreactivity in Alzheimer disease

Biophys. Biochem. Res. Commun.

(1993)

D.K. Strickland et al.

Sequence identity between the α₂-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor

J. Biol. Chem.

(1990)

D. van Gool et al.

α₂-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease

Neurobiol. Aging

(1993)

K.H. Weisgraber et al.

Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site

J. Biol. Chem.

(1982)

S.E. Williams et al.

A novel mechanism for controlling the activity of α₂-macroglobulin receptor/low density lipoprotein receptor-related protein

J. Biol. Chem.

(1992)

T. Wisniewski et al.

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

Neurosci. Lett.

(1992)

T. Wisniewski et al.

Apolipoprotein E: binding to soluble Alzheimer's β-amyloid

Biochem. Biophys. Res. Commun.

(1993)

P.V. Arriagada et al.

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Neurology

(1992)

P.V. Arriagada et al.

Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease

Neurology

(1992)

U. Beisiegel et al.

The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein

Nature

(1989)

W. Borth

α₂-Macroglobulin, a multifunctional binding protein with targeting characteristics

FASEB J.

(1992)

J. Davignon et al.

Apolipoprotein E polymorphism and atherosclerosis

Arteriosclerosis

(1988)

Cited by (1001)

Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins
2024, Neuron
The Apolipoprotein E gene (APOE) is of great interest due to its role as a risk factor for late-onset Alzheimer’s disease. ApoE is secreted by astrocytes in the central nervous system in high-density lipoprotein (HDL)-like lipoproteins. Structural models of lipidated ApoE of high resolution could aid in a mechanistic understanding of how ApoE functions in health and disease. Using monoclonal Fab and F(ab′)₂ fragments, we characterize the structure of lipidated ApoE on astrocyte-secreted lipoproteins. Our results provide support for the “double-belt” model of ApoE in nascent discoidal HDL-like lipoproteins, where two ApoE proteins wrap around the nanodisc in an antiparallel conformation. We further show that lipidated, recombinant ApoE accurately models astrocyte-secreted ApoE lipoproteins. Cryogenic electron microscopy of recombinant lipidated ApoE further supports ApoE adopting antiparallel dimers in nascent discoidal lipoproteins.
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease
2024, Molecular Therapy
Epidemiological studies show that individuals who carry the relatively uncommon APOE ε2 allele rarely develop Alzheimer disease, and if they do, they have a later age of onset, milder clinical course, and less severe neuropathological findings than people without this allele. The contrast is especially stark when compared with the major genetic risk factor for Alzheimer disease, APOE ε4, which has an age of onset several decades earlier, a more aggressive clinical course and more severe neuropathological findings, especially in terms of the amount of amyloid deposition. Here, we demonstrate that brain exposure to APOE ε2 via a gene therapy approach, which bathes the entire cortical mantle in the gene product after transduction of the ependyma, reduces Aβ plaque deposition, neurodegenerative synaptic loss, and, remarkably, reduces microglial activation in an APP/PS1 mouse model despite continued expression of human APOE ε4. This result suggests a promising protective effect of exogenous APOE ε2 and reveals a cell nonautonomous effect of the protein on microglial activation, which we show is similar to plaque-associated microglia in the brain of Alzheimer disease patients who inherit APOE ε2. These data increase the potential that an APOE ε2 therapeutic could be effective in Alzheimer disease, even in individuals born with the risky ε4 allele.
ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury
2023, Neurotherapeutics
The lack of targeted therapies for traumatic brain injury (TBI) remains a compelling clinical unmet need. Although knowledge of the pathophysiologic cascades involved in TBI has expanded rapidly, the development of novel pharmacological therapies has remained largely stagnant. Difficulties in creating animal models that recapitulate the different facets of clinical TBI pathology and flaws in the design of clinical trials have contributed to the ongoing failures in neuroprotective drug development. Furthermore, multiple pathophysiological mechanisms initiated early after TBI that progress in the subacute and chronic setting may limit the potential of traditional approaches that target a specific cellular pathway for acute therapeutic intervention. We describe a reverse translational approach that focuses on translating endogenous mechanisms known to influence outcomes after TBI to develop druggable targets. In particular, numerous clinical observations have demonstrated an association between apolipoprotein E (apoE) polymorphism and functional recovery after brain injury. ApoE has been shown to mitigate the response to acute brain injury by exerting immunomodulatory properties that reduce secondary tissue injury as well as protecting neurons from excitotoxicity. CN-105 represents an apoE mimetic peptide that can effectively penetrate the CNS compartment and retains the neuroprotective properties of the intact protein.
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
2023, Revue Neurologique
Alzheimer's disease (AD) is a multi-etiology disease. The biological system of AD is associated with multidomain genetic, molecular, cellular, and network brain dysfunctions, interacting with central and peripheral immunity. These dysfunctions have been primarily conceptualized according to the assumption that amyloid deposition in the brain, whether from a stochastic or a genetic accident, is the upstream pathological change. However, the arborescence of AD pathological changes suggests that a single amyloid pathway might be too restrictive or inconsistent with a cascading effect. In this review, we discuss the recent human studies of late-onset AD pathophysiology in an attempt to establish a general updated view focusing on the early stages. Several factors highlight heterogenous multi-cellular pathological changes in AD, which seem to work in a self-amplifying manner with amyloid and tau pathologies. Neuroinflammation has an increasing importance as a major pathological driver, and perhaps as a convergent biological basis of aging, genetic, lifestyle and environmental risk factors.
Investigating the effect of human apolipoprotein E isoforms on expression level of CLS and MINO genes involved in mitochondrial function in transgenic Drosophila model
2023, Animal Gene
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by aberrant lipid metabolism and mitochondrial dysfunction, features related to mitochondria-associated ER membranes (MAM). ApoE is recognized as the major AD risk factor. Human ApoE has three isoforms including Apoε2, Apoε3 and Apoε4. It has revealed that ε4 allele carriers are at higher risk of developing AD than ε3 allele carriers. Given that Apoε4 is a major AD risk factor and that MAM dysfunction in lipid metabolism may affect mitochondrial function, we assessed the expression pattern of cardiolipin synthetase (CLS) and glycerol-3-phosphate acyltransferase 2 (MINO) genes in Drosophila model of AD. To the best of our knowledge, this is the first study to investigate the effect of ApoE isoforms on mitochondrial function in Drosophila model of AD. RNA extraction was performed using glazt2a.gal4.UAS.hapoe transgenic flies harboring Apoε isoforms. Following cDNA synthesis, mRNA expression levels of target (CLS and MINO) and housekeeping (eEF1α) genes were measured by qRT-PCR. Our results did not show a significant decrease in CLS and MINO expression level in Apoɛ3 and Apoɛ4 groups as compared to the control. Although this reduction was not statistically significant, the decreasing trend indicates a kind of disruption in lipid biosynthesis and may directly affect mitochondrial function. Though the impact of Apoɛ4 on AD pathogenesis has been elucidated, the exact mechanism through which Apoɛ4 mediates AD progression is still unknown. Investigating the biology of ApoE isoforms using both human and AD animal models is recommended.
Molecular insights into the pathogenic impact of vitamin D deficiency in neurological disorders
2023, Biomedicine and Pharmacotherapy
Neurological disorders are the major cause of disability, leading to a decrease in quality of life by impairing cognitive, sensorimotor, and motor functioning. Several factors have been proposed in the pathogenesis of neurobehavioral changes, including nutritional, environmental, and genetic predisposition. Vitamin D (VD) is an environmental and nutritional factor that is widely distributed in the central nervous system's subcortical grey matter, neurons of the substantia nigra, hippocampus, thalamus, and hypothalamus. It is implicated in the regulation of several brain functions by preserving neuronal structures. It is a hormone rather than a nutritional vitamin that exerts a regulatory role in the pathophysiology of several neurological disorders, including Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. A growing body of epidemiological evidence suggests that VD is critical in neuronal development and shows neuroprotective effects by influencing the production and release of neurotrophins, antioxidants, immunomodulatory, regulation of intracellular calcium balance, and direct effect on the growth and differentiation of nerve cells. This review provides up-to-date and comprehensive information on vitamin D deficiency, risk factors, and clinical and preclinical evidence on its relationship with neurological disorders. Furthermore, this review provides mechanistic insight into the implications of vitamin D and its deficiency on the pathogenesis of neurological disorders. Thus, an understanding of the crucial role of vitamin D in the neurobiology of neurodegenerative disorders can assist in the better management of vitamin D-deficient individuals.

View all citing articles on Scopus

View full text

Neuron

ArticleApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions

Abstract

Cell

FEBS Lett.

J. Biol. Chem.

Trends Pharmacol. Sci.

J. Biol. Chem.

J. Lipid Res.

Brain Res.

Biochem. Biophys. Acta

Mol. Brain Res.

Neuron

Biophys. Biochem. Res. Commun.

J. Biol. Chem.

Neurobiol. Aging

J. Biol. Chem.

J. Biol. Chem.

Neurosci. Lett.

Biochem. Biophys. Res. Commun.

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Neurology

Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease

Neurology

The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein

Nature

α2-Macroglobulin, a multifunctional binding protein with targeting characteristics

FASEB J.

Apolipoprotein E polymorphism and atherosclerosis

Arteriosclerosis

Article
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions

α₂-Macroglobulin, a multifunctional binding protein with targeting characteristics